SI3423082T1 - Liraglutid pri kardiovaskularnih stanjih - Google Patents
Liraglutid pri kardiovaskularnih stanjihInfo
- Publication number
- SI3423082T1 SI3423082T1 SI201730917T SI201730917T SI3423082T1 SI 3423082 T1 SI3423082 T1 SI 3423082T1 SI 201730917 T SI201730917 T SI 201730917T SI 201730917 T SI201730917 T SI 201730917T SI 3423082 T1 SI3423082 T1 SI 3423082T1
- Authority
- SI
- Slovenia
- Prior art keywords
- liraglutide
- cardiovascular conditions
- cardiovascular
- conditions
- Prior art date
Links
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title 1
- 108010019598 Liraglutide Proteins 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 229960002701 liraglutide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158739 | 2016-03-04 | ||
| EP16173917 | 2016-06-10 | ||
| EP16001329 | 2016-06-13 | ||
| US15/401,651 US9968659B2 (en) | 2016-03-04 | 2017-01-09 | Liraglutide in cardiovascular conditions |
| PCT/EP2017/054990 WO2017149112A1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
| EP17710160.7A EP3423082B1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3423082T1 true SI3423082T1 (sl) | 2021-10-29 |
Family
ID=59723004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730917T SI3423082T1 (sl) | 2016-03-04 | 2017-03-03 | Liraglutid pri kardiovaskularnih stanjih |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968659B2 (enExample) |
| EP (1) | EP3423082B1 (enExample) |
| JP (1) | JP6940512B2 (enExample) |
| KR (1) | KR102417455B1 (enExample) |
| CN (2) | CN108778317A (enExample) |
| AU (2) | AU2017225841A1 (enExample) |
| BR (1) | BR112018067344A2 (enExample) |
| CA (1) | CA3013532C (enExample) |
| CL (1) | CL2018002515A1 (enExample) |
| DK (1) | DK3423082T5 (enExample) |
| ES (1) | ES2893755T3 (enExample) |
| HR (1) | HRP20211492T1 (enExample) |
| HU (1) | HUE055844T2 (enExample) |
| IL (1) | IL261169B (enExample) |
| MA (1) | MA43704A (enExample) |
| MX (1) | MX394179B (enExample) |
| MY (1) | MY195657A (enExample) |
| PH (1) | PH12018501844B1 (enExample) |
| PL (1) | PL3423082T3 (enExample) |
| RS (1) | RS62501B1 (enExample) |
| RU (1) | RU2745604C2 (enExample) |
| SI (1) | SI3423082T1 (enExample) |
| WO (1) | WO2017149112A1 (enExample) |
| ZA (1) | ZA201805538B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| PL3448416T3 (pl) | 2016-04-28 | 2022-11-07 | Novo Nordisk A/S | Semaglutyd w schorzeniach sercowo-naczyniowych |
| CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
| EP4262873A4 (en) * | 2020-12-16 | 2024-12-11 | The Chinese University of Hong Kong | A method for reversing aging brain functional decline |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808203A (en) | 1997-05-12 | 1998-09-15 | Medrad, Inc. | Fluid pressure measurement devices |
| EP1494704A1 (en) * | 2002-04-04 | 2005-01-12 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| KR101243648B1 (ko) * | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
| CN101056650A (zh) * | 2004-11-12 | 2007-10-17 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| EP2190872B1 (en) * | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| EP2566502A4 (en) | 2010-05-04 | 2013-10-09 | Glaxosmithkline Llc | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION |
| PH12012502524A1 (en) | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| EP2854812A1 (en) | 2012-05-24 | 2015-04-08 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| JP2016510795A (ja) | 2013-03-15 | 2016-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| KR102238860B1 (ko) | 2013-06-14 | 2021-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 이의 합병증의 치료를 위한 dpp-4 억제제 |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
-
2017
- 2017-01-09 US US15/401,651 patent/US9968659B2/en active Active
- 2017-03-03 BR BR112018067344A patent/BR112018067344A2/pt unknown
- 2017-03-03 CN CN201780015266.5A patent/CN108778317A/zh active Pending
- 2017-03-03 MX MX2018010097A patent/MX394179B/es unknown
- 2017-03-03 PL PL17710160T patent/PL3423082T3/pl unknown
- 2017-03-03 EP EP17710160.7A patent/EP3423082B1/en not_active Revoked
- 2017-03-03 CN CN202310320736.6A patent/CN116327897A/zh not_active Withdrawn
- 2017-03-03 PH PH1/2018/501844A patent/PH12018501844B1/en unknown
- 2017-03-03 MY MYPI2018702782A patent/MY195657A/en unknown
- 2017-03-03 WO PCT/EP2017/054990 patent/WO2017149112A1/en not_active Ceased
- 2017-03-03 AU AU2017225841A patent/AU2017225841A1/en not_active Abandoned
- 2017-03-03 HU HUE17710160A patent/HUE055844T2/hu unknown
- 2017-03-03 MA MA043704A patent/MA43704A/fr unknown
- 2017-03-03 JP JP2018546477A patent/JP6940512B2/ja active Active
- 2017-03-03 RS RS20211250A patent/RS62501B1/sr unknown
- 2017-03-03 KR KR1020187026962A patent/KR102417455B1/ko active Active
- 2017-03-03 DK DK17710160.7T patent/DK3423082T5/da active
- 2017-03-03 CA CA3013532A patent/CA3013532C/en not_active Expired - Fee Related
- 2017-03-03 ES ES17710160T patent/ES2893755T3/es active Active
- 2017-03-03 HR HRP20211492TT patent/HRP20211492T1/hr unknown
- 2017-03-03 SI SI201730917T patent/SI3423082T1/sl unknown
- 2017-03-03 RU RU2018134061A patent/RU2745604C2/ru active
-
2018
- 2018-04-18 US US15/956,445 patent/US20180236038A1/en not_active Abandoned
- 2018-08-15 IL IL26116918A patent/IL261169B/en unknown
- 2018-08-20 ZA ZA2018/05538A patent/ZA201805538B/en unknown
- 2018-09-03 CL CL2018002515A patent/CL2018002515A1/es unknown
-
2024
- 2024-03-26 AU AU2024201937A patent/AU2024201937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3261455T3 (pl) | Syropy allulozowe | |
| GB201502197D0 (en) | Interconnect | |
| IL262390A (en) | Semaglutide in cardiovascular conditions | |
| IL256020B (en) | Igfbp3 and uses thereof | |
| GB201517368D0 (en) | Value | |
| GB201507032D0 (en) | Allulose syrups | |
| IL248180A0 (en) | Ionines are stable in the presence of hydroxide | |
| GB201719541D0 (en) | Cell Lines | |
| PL3313757T3 (pl) | Sortownik liniowy | |
| ZA201805538B (en) | Liraglutide in cardiovascular conditions | |
| GB201521206D0 (en) | Title in german | |
| GB201521190D0 (en) | Application in german | |
| GB201518745D0 (en) | Buoyancy component | |
| GB201416195D0 (en) | Recreational Bobsleigh | |
| SG11201802839VA (en) | Sweetness enhancement | |
| GB201523035D0 (en) | In terferometry | |
| GB201521191D0 (en) | Application in german | |
| PT3423082T (pt) | Liraglutida em condições cardiovasculares | |
| GB201514185D0 (en) | Improvements in laptop cases | |
| GB201508643D0 (en) | Improvements in shirts | |
| PT3448416T (pt) | Semaglutido em condições cardiovasculares | |
| GB201513676D0 (en) | Inflatables / deflatables | |
| GB201618109D0 (en) | Improvements in drawing boards | |
| GB2522268B (en) | Recreational swing | |
| GB201512547D0 (en) | Washing lines |